Breast Cancer

Resistance to aromatase inhibitors (AIs) is a growing concern in patients with advanced hormone receptor (HR)–positive, HER2-negative breast cancer, said Hope S. Rugo, MD, FASCO, who added that although fulvestrant (Faslodex) has shown some activity in patients who develop ESR1 mutations, more effective treatment options are needed.

Drug prices for cancer care are rising considerably, but biosimilars are poised to help patients with cancer handle these prices. Particularly, patients with breast cancer.

While physicians are looking to further subclassify TNBC to narrow treatment options, not all of these classifications are actionable in the clinic.

Multiple CDK4/6 inhibitors have shown impressive OS survival benefit in multiples studies of patients with metastatic HR+ breast cancer.

Despite advanced technology and new treatment breakthroughs in cancer care, treatment disparity remains among African American women with breast cancer.

At the 2019 ESMO Congress, the phase II KATE2 trial missed its primary endpoint but found promising results for a subgroup of patients with HER2-positive breast cancer with a PD-L1 expression.

Immunotherapy is sometimes considered solely for the later stages of treatment, but findings from a new study show promise for immunotherapy in treating patients with early breast cancer.

One expert details why axillary lymph node dissection is vital in the treatment of patients with breast cancer.

By implementing a survivorship program at their cancer center, oncology nurses were able to improve the quality of life in patients with recurrent breast cancer.

Patients with the highest risk of developing a BRCA mutation are not being tested earlier enough and developing these mutations when it's too late. Clinicians can change that.

The FDA has granted a priority review for Trastuzumab Deruxtecan to treat HER2-positive metastatic breast cancer based on the results from two new studies.

At the 2019 ESMO Congress, results for the MONALEESA-3 trial showed promise for patients with breast cancer and had many experts excited over its clinical implications.

The future of treating patients with triple-negative breast cancer is bright, but more needs to be done to address mutations early on in the course of the disease.

Overall survival results from the MONALESSA-3 phase III trial showed positive results for patients with advanced breast cancer, but toxicities related to the use of ribociclib still need to be addressed.

Management of axillary lymph nodes in patients with breast cancer has undergone some positive changes, but more research is required to treat this patient population properly.

Experts are looking to use immunotherapy in different ways for patients with early-stage breast cancer.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Patients with a higher likelihood to develop BRCA 1 or BRCA 2 mutations are slipping through the cracks, making testing for these mutations a vital part of any breast cancer treatment plan.

For patients with breast cancer with a PDL1 expression, a new treatment targeting immune cells could make a major difference.

Atezolizumab, along with T-DM1, showed benefit for a subgroup of patients with breast cancer.

A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor-positive breast cancer.

An expert discusses 2 new surgical treatments for breast cancer-associated lymphedema.

About a third of breast cancer survivors are still living with fatigue and reduced exercise capacity after treatment ends.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Treating patients with HER2-positive metastatic breast cancer is difficult, and patients can fail multiple lines of direct treatment. But now, the FDA has accepted a supplemental new drug application for a combination treatment to help these patients failing multiple treatments.

Here are the top 5 Oncology Nursing News stories for August 2019.

At the 3rd Annual School of Nursing Oncology, Oncology Nursing News had the chance to sit down with Madelaine Kuiper, MSN, RN, and talk about what nurses need to understand about the evolving landscape of breast cancer treatment.

While the US Preventative Services Task Force expanded their recommendations of who should be tested for BRCA mutations, there are still issues left unaddressed, according to one expert.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

With various FDA approvals in the last year alone, nurses must stay up-to-date on the changing treatment landscape of breast cancer to properly treat these patients.